RT Book, Section
A1 Faulkner, Michele A.
A2 Sutton, S. Scott
SR Print(0)
ID 7254546
T1 Chapter 50. Parkinson Disease
T2 McGraw-Hill's NAPLEX® Review Guide
YR 2011
FD 2011
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-175562-7
LK accesspharmacy.mhmedical.com/content.aspx?aid=7254546
RD 2024/04/16
AB Parkinson  disease  (PD)  is  a  highly  prevalent  neurodegenerative  disorder  secondary  in  prevalence  only  to  Alzheimer  disease.1  Approximately  2%  of  the  geriatric  population  is  affected,  though  younger  persons  can  also  develop  the  disease.2  The  mean  age  of  onset  is  65  years,  and  men  are  affected  more  often  than  women.  Associated  morbidity  is  substantial,  and  results  in  increased  hospitalizations,  increased  prescription  drug  utilization  and  more  frequent  placement  in  long-term  care  facilities  as  compared  to  the  general  population.3  Though  in  most  cases  persons  with  PD  can  expect  to  live  into  old  age,  their  life  expectancy  is  somewhat  shorter  than  average.4,5  The  disease  is  progressive,  and  no  cure  has  been  identified  to  date.